NASDAQ:AMED - Free Report ) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 344,795 shares of the health services provider's stock, valued at approximately $32,776,000. Amedisys accounts for about 1.7% of Segantii Capital Management Ltd's investment portfolio, making the stock its 14th largest holding. Segantii Capital Management Ltd owned approximately 1.06% of Amedisys at the end of the most recent quarter.
Get Amedisys alerts:
Sign Up
A number of other institutional investors also recently modified their holdings of the business. Commonwealth Equity Services LLC lifted its position in shares of Amedisys by 2.9% during the third quarter. Commonwealth Equity Services LLC now owns 3,896 shares of the health services provider's stock worth $364,000 after acquiring an additional 110 shares in the last quarter. Xponance Inc. boosted its stake in Amedisys by 3.2% in the 3rd quarter. Xponance Inc. now owns 4,076 shares of the health services provider's stock worth $381,000 after purchasing an additional 125 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Amedisys by 12.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,893 shares of the health services provider's stock valued at $550,000 after buying an additional 663 shares in the last quarter. ING Groep NV lifted its holdings in shares of Amedisys by 257.4% in the third quarter. ING Groep NV now owns 189,800 shares of the health services provider's stock worth $17,727,000 after buying an additional 136,700 shares in the last quarter. Finally, Olympiad Research LP boosted its position in shares of Amedisys by 94.9% in the third quarter. Olympiad Research LP now owns 15,968 shares of the health services provider's stock valued at $1,491,000 after acquiring an additional 7,777 shares during the period. 94.36% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys Price Performance AMED traded up $0.47 during trading on Thursday, reaching $94.55. The stock had a trading volume of 462,638 shares, compared to its average volume of 277,434. The business has a 50-day moving average of $92.35 and a 200-day moving average of $93.34. Amedisys, Inc. has a one year low of $73.10 and a one year high of $96.44. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.09. The stock has a market cap of $3.09 billion, a PE ratio of -147.73, a PEG ratio of 3.43 and a beta of 0.84.
Amedisys (NASDAQ:AMED - Get Free Report ) last announced its quarterly earnings data on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. The firm had revenue of $571.41 million for the quarter, compared to analyst estimates of $565.38 million. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The company's revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.00 EPS. As a group, equities research analysts anticipate that Amedisys, Inc. will post 4.57 EPS for the current fiscal year.
Analyst Ratings Changes A number of analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $101.00 target price on shares of Amedisys in a report on Thursday, April 25th. Royal Bank of Canada increased their price objective on Amedisys from $97.00 to $100.00 and gave the stock an "outperform" rating in a research report on Monday, March 25th. Raymond James reissued a "market perform" rating on shares of Amedisys in a research note on Tuesday, March 26th. Finally, StockNews.com upgraded Amedisys from a "hold" rating to a "buy" rating in a research note on Saturday, May 4th. Seven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $100.80.
Get Our Latest Stock Report on Amedisys
Amedisys Company Profile (
Free Report )
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Stories
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
